<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35379512</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1806-4841</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>97</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Season>May-Jun</Season>
            </PubDate>
          </JournalIssue>
          <Title>Anais brasileiros de dermatologia</Title>
          <ISOAbbreviation>An Bras Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Leprosy: clinical and immunopathological characteristics.</ArticleTitle>
        <Pagination>
          <StartPage>338</StartPage>
          <EndPage>347</EndPage>
          <MedlinePgn>338-347</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.abd.2021.08.006</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0365-0596(22)00026-5</ELocationID>
        <Abstract>
          <AbstractText>Leprosy, a disease caused by Mycobacterium leprae, has polymorphic neurocutaneous manifestations strongly correlated with the host immune response. Peripheral neural damage can lead to sensory and motor losses, as well as deformities of the hands and feet. Both innate and acquired immune responses are involved, but the disease has been classically described along a Th1/Th2 spectrum, where the Th1 pole corresponds to the more limited presentations and the Th2 to the multibacillary ones. The aim of this review is to discuss this dichotomy in light of the current knowledge of the cytokines, T helper subpopulations, and regulatory T cells involved in each presentation of leprosy. The text will also address leprosy reactions related to increased inflammatory activity in both limited and multibacillary presentations, leading to exacerbation of chronic signs and symptoms and/or the development of new ones. Despite the efforts of many research groups around the world, there is no standardized serological test/biological marker for diagnosis so far, even in endemic areas, which could contribute to the eradication of leprosy.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Froes</LastName>
            <ForeName>Luis Alberto Ribeiro</ForeName>
            <Initials>LAR</Initials>
            <Suffix>Junior</Suffix>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Faculty of Medicine, Universidade de São Paulo, São Paulo, SP, Brazil. Electronic address: lulafroes@usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sotto</LastName>
            <ForeName>Mirian Nacagami</ForeName>
            <Initials>MN</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Faculty of Medicine, Universidade de São Paulo, São Paulo, SP, Brazil; Department of Dermatology, Faculty of Medicine, Universidade de São Paulo, São Paulo, SP, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Trindade</LastName>
            <ForeName>Maria Angela Bianconcini</ForeName>
            <Initials>MAB</Initials>
            <AffiliationInfo>
              <Affiliation>LIM56, Hospital das Clínicas, Faculty of Medicine, Universidade de São Paulo, São Paulo, SP, Brazil; Instituto de Saúde, Secretaria de Estado da Saúde, São Paulo, SP, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Spain</Country>
        <MedlineTA>An Bras Dermatol</MedlineTA>
        <NlmUniqueID>0067662</NlmUniqueID>
        <ISSNLinking>0365-0596</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007918" MajorTopicYN="Y">Leprosy</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009166" MajorTopicYN="N">Mycobacterium leprae</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Immunology</Keyword>
        <Keyword MajorTopicYN="N">Leprosy</Keyword>
        <Keyword MajorTopicYN="N">Lymphocyte activation</Keyword>
        <Keyword MajorTopicYN="N">Mycobacterium leprae</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35379512</ArticleId>
        <ArticleId IdType="doi">10.1016/j.abd.2021.08.006</ArticleId>
        <ArticleId IdType="pii">S0365-0596(22)00026-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
